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Editorial
Over the last century, the life sciences have 
generated important insights in functional 
processes of life, mainly due to the broad 
introduction of reductionism and experi-
mental manipulation in biology and medi-
cal research during the 20th century [1]. 
On the basis of this extremely successful 
research paradigm, amongst others, scien-
tists rationally dissected multiple molecular 
mechanisms of ‘living systems’, identified 
the causes of inheritable severe disorders and 
developed blockbuster drugs.
For example, it is nowadays a widely 
known textbook knowledge that some rare 
mutations can cause severe monogenetic 
diseases due to the malfunction of key 
proteins. A number of simple biochemical 
or PCR-based gene tests can be applied to 
diagnose monogenic diseases. Nevertheless, 
recent genome-wide association studies 
(GWAS) revealed that for many multi-
factorial diseases, the disease phenotypes 
cannot be mono-causally derived from the 
action of individual genes or proteins [2]. 
These genetic and other functional analy-
ses not surprisingly indicated that (slowly 
developing) complex diseases such as ath-
erosclerosis are rather the result of the rising 
deregulation of interconnected genes or the 
dysfunction of molecular pathways [3]. In 
this context, cellular clusters of chemically 
modifiable proteins exert many important 
biological functions, closely at the  solubility 
equilibrium in the cell.
Moreover, in line with GWAS of many 
diseases, recent cancer genomics studies 
showed that instead of mutation frequency, 
patterns of mutations in key oncogenes or 
tumor suppressor genes are specific for the 
disease [4]. Mutation pattern information 
can be used to classify disease states by 
applying cancer mutation databases [5]. 
Although a large number of mutations 
have been identified in cancer, the impor-
tant driver mutations appear to be accu-
mulated in fewer numbers of pathways and 
cellular processes, which  contribute to a 
selective cell growth advantage.
Strikingly, even genetically identical 
individuals can vary in their phenotypic 
traits due to environmental and stochas-
tic effects. In general, complex biological 
phenomena depend on molecules such as 
proteins, just as the meaning of this text 
depends on the use of letters and words. 
But many biological or medical phenom-
ena we are eventually interested in are pri-
marily based on the emerging properties 
and functions of structured molecular net-
works, influenced by environmental and 
stochastic factors, which cannot be suffi-
ciently described or explained by the ‘parts 
of the sum’ of mechanistic events of few 
dissected biomolecules [6]. This organisa-
tional principle might just be part of the 
often mentioned ‘complexity’ in biology.
Network-based organization of bio-
molecules leads to evolutionary beneficial 
redundancy, plasticity and flexibility of 
physiology. Key biological functions that 
emerge – depending on the cellular or other 
biological contexts [7] – on the pathway 
level are more robust against environmen-
tal changes and genetic alterations than 
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functions that would be represented by only a few proteins. Single-
gene or single-protein events are potentially causal for disease when 
the individual effect on a disease is strong and the variance is small 
across individuals [8]. However, this scenario is (fortunately) the 
exception. Most common complex diseases seem to be the result 
of an unbalance of the effects of environmental factors and an 
inherited susceptibility leading to minor variation in the  expression 
or the activities of many interacting gene products or proteins.
Nevertheless, it is not surprising that molecular biologists 
or biochemists often favor elegant, rather simple mechanisms 
for the understanding of complex diseases and physiology. But 
this approach seems to be limited to experimentally separable 
aspects of biology. Moreover, many researchers hope to identify 
few causative or at least surrogate biomarkers, which can be of 
additional value for diagnosis and drug monitoring. The largely 
successful reductionist approach will deliver further insightful 
detailed information in the life sciences, in particular to under-
stand functionalities of the so far largely uncharacterized sev-
eral thousands of proteins. However, complex disease processes 
including environmental factors or drug treatments can interfere 
with many proteins or molecular networks – in many different 
cell types or tissues. Thus, the current inefficiencies in complex 
disease management and pharmacological development may 
argue for complementary research paradigms.
Along with the availability of new powerful data gathering and 
data handling tools, we are now in a good position to develop 
efficient models to explain non-separable properties of (molecu-
lar) pathways and biological systems [9]. Furthermore, for many 
diseases early diagnosis would benefit from more sophisticated 
biomarker analyses to provide evidence for efficient preventive 
intervention years before the irreversible outbreak of complex 
diseases. Moreover, more efficient characterization of drug candi-
dates in early preclinical and clinical phases would result in higher 
success rates of drug development and treatment.
In practice, pattern recognition is a powerful and robust ana-
lytical approach and has been successfully applied for many 
purposes. In the proteomics field, in particular MALDI mass 
spectrometry, detection of mass patterns or profiles of unidenti-
fied proteins derived from whole bacterial cells has become a very 
popular, cost-efficient approach for routine microbial diagnostics 
and is now widely replacing traditional biochemical tests in the 
clinics [10,11]. Similar mass spectrometry-based protein pattern 
detection approaches were also applied for disease classification 
by using various body fluids to enrich in standardized procedures 
fragments of protease-digested proteins of human patients [12,13]. 
However, although useful for diagnostics, these two MALDI 
mass spectrometry-based molecular phenotypic approaches could 
not reveal much biological insight.
Biomolecule set or molecular pathway analysis is based on the 
idea that cellular or physiological changes manifest at the level 
of co-regulated, interacting or co-evolving biomolecules, rather 
than individually [6]. As we have shown recently, analyses of 
comprehensive sets of identified, well-characterized proteins can 
efficiently decipher functional molecular networks of complex 
diseases such as diet-induced insulin resistance and can help to 
assess drug treatments in vivo [14]. This protein set enrichment 
analysis approach [14–16] adapts the concept of gene set enrich-
ment analysis [17], a popular bioinformatics tool to determine 
whether an a priori defined set of related biomolecules indicates 
statistically significant, concordant differences between various 
biological states (more information can be found at [101]). Gene 
or protein sets can be defined by the researcher, for example, by 
consulting various publicly available pathway databases. Using 
gene set enrichment analysis or protein set enrichment analysis, 
the whole transcriptomics or proteomics dataset, including only 
marginally or completely unregulated mRNAs or proteins, is 
used for analysis.
Using nano-liquid chromatography coupled to electrospray 
ionization mass spectrometry we identified and quantitatively 
analyzed several thousands of proteins including posttranslational 
modifications such as phosphosites in peripheral metabolic target 
tissues [14]. Applying protein set enrichment and pathway analyses, 
we discovered striking changes in protein pathways that indicated 
differential regulation of cellular and tissue homeostasis during 
high fat diet and antidiabetic medication. For example, in the 
case of the diabetes drug rosiglitazone, we could early on extract 
dysregulated protein pathways in the heart, even after only a few 
weeks of treatment and long before any typical pathological car-
diovascular phenotypes could be observed. Further, using pro-
tein set analyses in conjunction with widely applied physiological 
assays, we could exclude the known side effects of rosiglitazone for 
another, new class of natural antidiabetics, the amorfrutins [18].
In many biological systems it seems that transcriptional (or 
mRNA) networks in cells are at least in part affected by sto-
chastic processes due to Brownian motion of the mRNAs, in 
particular, in the case of low-abundant transcripts. In contrast, 
proteins tend to be expressed in larger quantities, making cel-
lular protein networks rather non-stochastic and more robust 
against environmental challenges. In drug-treated or non-treated 
insulin-resistant obese mice, we observed only a subtle variation 
of individual protein expression for most (rather abundant) pro-
teins. Interestingly, we observed striking consistence of RNA and 
protein expression on the pathway but much less on the individual 
gene-protein level [14]. These results strengthened the idea that 
physiological outcomes arise from the context-specific interaction 
of various biomolecules, which can be grouped in functionally 
“…many biological or medical phenomena we are 
eventually interested in are primarily based on the 
emerging properties and functions of structured 
molecular networks, influenced by environmental 
and stochastic factors.”
“Biomolecule set or molecular pathway analysis is 
based on the idea that cellular or physiological 
changes manifest at the level of co-regulated, 
interacting or co-evolving biomolecules, rather 
than individually.”

































































distinct gene or protein sets. Moreover, the observed stability of 
regulation on the level of sets of proteins makes the presented 
approach largely independent from potentially non-identified 
proteins or still  missing protein information. 
Protein set analysis will strongly benefit from further instru-
mental improvements such as detection speed and sensitivity of 
applied electrospray ionization mass spectrometers. For example, 
modern benchtop orbitrap mass spectrometers utilizing electro-
spray ionization can process single-shot proteome analyses in a few 
hours [19], making large-scale application of protein set analyses 
easily doable. Using isotopically labeled human reference cells or 
well-controlled label-free protocols [20], protein set analysis can 
be extended for clinical applications such as early disease detec-
tion and treatment monitoring using biopsies or other material 
of human patients. The focus on the sets of proteins instead of 
only few biomarkers may also reduce the frequently encountered 
problem of interpretation of inter-patient variability. 
In a nutshell, protein set analysis offers great opportunities for 
basic research and clinical applications [14]. This functional large-
scale proteomics methodology can produce highly informative 
data for systems-based research. Furthermore, protein set analysis 
can provide powerful diagnostic read-out even at an early stage 
and in an unbiased way to monitor the effects of drug treatment, 
in the animal model or in the human patient. The mass spectrom-
etry technologies required for protein set analysis will be mature 
for large-scale applications in the very near future to initiate first 
clinical studies. 
Comprehensive quantitative protein expression and modifica-
tion data will be important to model disease states and treatment 
regimes. Protein set analysis is a promising approach to adequately 
grasp biological complexity and to understand and efficiently 
diagnose complex diseases, monitor physiological changes and 
successfully develops new drugs.
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